Director/PDMR Shareholding

RNS Number : 3028A

Genedrive PLC

10 September 2018

 

Notification and public disclosure of transactions by persons discharging

managerial responsibilities and persons closely associated with them

genedrive plc (LSE: GDR) ("genedrive" or the "Company"), the near patient molecular diagnostics company, announces that it has granted share options ("Options") to a member of its senior management team to acquire a total of 30,000 ordinary shares of 1.5p each in the capital of the Company under the Company's Share Option Scheme.

The Options have been granted with an exercise price equal to the close price on the day before grant and vest after a period of three years. The Options are exercisable over the period of 10 years from the date of grant.

The information set out below is provided in accordance with the requirements of Article 19(3) of the EU Market Abuse Regulation No 596/2014.

1.	Details of the person discharging managerial responsibilities / person closely associated
a.	Name	1.   Colleen Pythian
2.	Reason for the notification
a.	Position/status	1.   Director of Quality & Regulation
a.	Initial notification /Amendment	Initial notification
3.	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a.	Name	genedrive plc
b.	LEI	213800ZYODIRZ87Y4K14
4.	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a.	Description of the Financial instrument, type of instrument Identification code	Options over ordinary shares of 1.5 pence each
b.	Nature of the transaction	Grant of options pursuant to and in accordance with the terms of the Company's Share Option Scheme dated 29 November 2017.
c.	Price(s) and volume(s)	Option price(s) Volume(s) Colleen Pythian 27.50p 30,000
d.	Aggregated information ·      Aggregated volume ·      Price	N/A
e.	Date of the transaction	2018-09-06; UTC time
f.	Place of the transaction	Outside trading venue - shares to be admitted to AIM market of London Stock Exchange plc on exercise of options

For further details please contact:

genedrive plc	[phone]
David Budd: CEO
Matthew Fowler: CFO
Peel Hunt LLP	[phone]
James Steel
Oliver Jackson
Consilium Strategic Communications	[phone]
Chris Gardner
Matthew Neal
Laura Thornton
[e-mail]

 

END

 

 

DSHEAANEFLLPEFF